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OBJECTIVES The goal of this study was to further define the role of nesiritide (human b-type natriuretic
peptide) in the therapy of decompensated heart failure (HF) by assessing the hemodynamic
effects of three doses (0.015, 0.03 and 0.06 mg/kg/min) administered by continuous
intravenous (IV) infusion over 24 h as compared with placebo.
BACKGROUND Previous studies have shown beneficial hemodynamic, neurohormonal and renal effects of
bolus dose and 6-h infusion administration of nesiritide in HF patients. Longer term safety
and efficacy have not been studied.
METHODS This randomized, double-blind, placebo-controlled multicenter trial enrolled subjects with
symptomatic HF and systolic dysfunction (left ventricular ejection fraction #35%). Central
hemodynamics were assessed at baseline, during a 24-h IV infusion and for 4 h postinfusion.
RESULTS One hundred three subjects with New York Heart Association class II (6%), III (61%) or IV
(33%) HF were enrolled. Nesiritide produced significant reductions in pulmonary wedge
pressure (27% to 39% decrease by 6 h), mean right atrial pressure and systemic vascular
resistance, along with significant increases in cardiac index and stroke volume index, with no
significant effect on heart rate. Beneficial effects were evident at 1 h and were sustained
throughout the 24-h infusion.
CONCLUSIONS The rapid and sustained beneficial hemodynamic effects of nesiritide observed in this study
support its use as a first-line IV therapy for patients with symptomatic decompensated HF.
(J Am Coll Cardiol 1999;34:155–62) © 1999 by the American College of Cardiology
The prospect of steadily increasing numbers of heart failure
(HF) patients requiring hospital admission for episodes of
decompensation has stimulated a search for new therapeutic
agents that can safely produce rapid hemodynamic improve-
ment, shorten hospital stays and reduce the enormous costs
associated with this syndrome (1). Human b-type natri-
uretic peptide (hBNP), or brain natriuretic peptide, is a
32–amino acid peptide produced primarily in the heart by
the left ventricle (2). Endogenous hBNP levels are elevated
in patients with HF and serve as a sensitive and specific
serologic marker for left ventricular dysfunction (3),
prompting speculation that hBNP may play a role in the
modulation of cardiac and vascular function and fluid status
in this population (4). Exogenous hBNP has been assigned
the generic term nesiritide. Therapeutic doses of nesiritide
may have a role in the management of HF. Previous human
studies have shown that intravenous (IV) administration of
nesiritide produces vasodilation, antagonism of the renin–
aldosterone system, diuresis and natriuresis (5–8). When
administered to HF patients, IV bolus doses and 6-h
infusions of nesiritide were well tolerated and resulted in
significant dose-related reductions in pulmonary capillary
wedge pressure (PCWP), mean right atrial pressure
(MRAP) and systemic vascular resistance (SVR), with
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increases in cardiac index (CI) (9–11). These observations
suggest that nesiritide produces a unique combination of
desirable hemodynamic, neurohormonal and renal effects in
HF. To further define the role of nesiritide in the therapy of
HF, this study was designed to assess the hemodynamic
effects of three doses of nesiritide (0.015, 0.03 and 0.06
mg/kg/min) compared with placebo, administered as a
continuous IV infusion for 24 h in patients with advanced
HF. Secondary objectives included assessing the renal re-
sponse to and the safety of the continuous 24-h IV infusion.
METHODS
Subjects/randomization. For this randomized, double-
blind, placebo-controlled study, the investigational review
committees of all 16 participating study sites approved the
study protocol and informed consent document. Subjects
with New York Heart Association class II, III or IV HF
were admitted to the hospital and a pulmonary artery
flotation catheter was placed at least 90 min before baseline
central hemodynamic measurements were made and at least
2 h before the start of study drug. Once all eligibility criteria
(Table 1) were met, subjects were randomized into one of
four treatment groups: group 1, IV placebo bolus followed
by a placebo infusion; group 2, nesiritide 0.25-mg/kg IV
bolus followed by an infusion of 0.015 mg/kg/min; group 3,
nesiritide 0.5-mg/kg IV bolus followed by an infusion of
0.03 mg/kg/min; or group 4, nesiritide 1.0-mg/kg IV bolus
followed by an infusion of 0.06 mg/kg/min. Randomization
was stratified by study site. The randomization assigned
subjects to treatment groups 1, 2, 3 or 4 in a ratio of 1:1:1:1,
using an initial block of size 4 and subsequent blocks of size
8. All of the study drug, including placebo, was prepared in
identical infusion bags by study site personnel who were not
associated with the subject’s clinical management to ensure
blinding.
Treatment. Each subject received an IV loading bolus
followed by a continuous IV infusion of the study drug for
24 h. Nesiritide was supplied by Scios Inc. (Mountain View,
California). Placebo was a 5% dextrose in water solution
supplied by the hospital pharmacy. The infusion dose was to
remain constant for 24 h. If hypotension, defined as
symptomatic hypotension or systemic systolic blood pres-
sure (SBP) less than 80 to 85 mm Hg or a decrease in
PCWP below 10 mm Hg occurred, the infusion flow rate
was decreased by 50%. Only one dose reduction was
permitted; if hypotension or excessive PCWP reduction
persisted after dose reduction, the infusion was discontin-
ued. Any subject who required the discontinuation of study
drug infusion due to worsening heart failure was considered
a “treatment failure.” Dose could not be increased over the
originally assigned dose, or increased after a dose reduction.
Study protocol. Before study drug administration, beta-
adrenergic blocking agents and calcium channel blocking
agents were withheld for 48 h, and vasodilators, hydralazine
and angiotensin-converting enzyme inhibitors were with-
held for 12 to 24 h. During study drug infusion,
Abbreviations and Acronyms
CI 5 cardiac index
hBNP 5 human b-type natriuretic peptide
HF 5 heart failure
IV 5 intravenous
MRAP 5 mean right atrial pressure
PCWP 5 pulmonary capillary wedge pressure
SBP 5 systemic systolic blood pressure
SVR 5 systemic vascular resistance
Table 1. Inclusion and Exclusion Criteria
Inclusion criteria
● 18 years of age with NYHA class II, III or IV heart failure.
● Male; or female and infertile or using effective contraception.
● Systolic dysfunction, as evidenced by left ventricular ejection
fraction #35% (by either echocardiography or radionuclide or
contrast ventriculography within 12 months).
● Receiving chronic CHF medications (such as ACE inhibitors,
nitrates or hydralazine, with or without oral digoxin/diuretic
therapy) for at least 1 month, and on stable doses for $48 h.
● Fully understand and has signed the Informed Consent Form
before study procedures.
● PCWP $18 mm Hg and CI $2.7 liters/min/m2 at baseline.
Exclusion criteria
● Myocardial infarction within 2 months, unstable angina
within 4 weeks or any clinical evidence of active myocardial
ischemia.
● Significant valvular stenosis, hypertrophic, restrictive or
obstructive cardiomyopathy, constrictive pericarditis, primary
pulmonary hypertension, biopsy-proven active myocarditis or
complex congenital heart disease.
● Sustained ventricular tachycardia or ventricular fibrillation
within the past 2 weeks.
● Mobitz type II or third-degree heart block, unless the subject
had a permanent pacemaker.
● Stroke within 3 months or evidence of compromised central
nervous system perfusion.
● Serum creatinine .3.0 mg/dl.
● Serum sodium concentration ,125 mEq/liter or
.160 mEq/liter.
● Use of beta-blockers or calcium channel blockers within 48 h
before study drug.
● Inability to withhold ACE inhibitors, nitrates or hydralazine
for the protocol-specified time period before study drug
administration through completion of the 24-h study drug
infusion.
● Therapy with another investigational drug within 1 month
before study enrollment.
● Clinical condition or laboratory abnormality which may
increase the risks associated with study participation or may
interfere with the interpretation of study results.
ACE 5 angiotensin-converting enzyme; CHF 5 congestive heart failure; CI 5
cardiac index; NYHA 5 New York Heart Association; PCWP 5 pulmonary capillary
wedge pressure.
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angiotensin-converting enzyme inhibitors, vasodilators,
beta-blockers and calcium channel blockers were withheld;
digoxin, diuretics and antiarrhythmics were administered as
per the protocol if clinically indicated. Central hemodynam-
ics (PCWP, MRAP, SVR, CI), systemic blood pressure and
heart rate measurements were obtained at baseline, during
the study drug infusion at 1, 3, 6, 10 and 24 h, and at 2 and
4 h postinfusion. Additional measurements were taken
during any significant event. Cardiac index was derived
from body surface area and the mean of three consecutive
thermodilution measurements of cardiac output falling
within 15% of each other or the mean of three out of five
measurements (where the high and low values were discard-
ed). Total fluid intake and urine output were measured for
24 h after the start of study drug. Blood was drawn for
serum chemistry and hematology studies at baseline, within
24 h after discontinuation of study drug and between days
20 and 30. Blood for plasma hBNP levels was drawn 15 min
preinfusion, 0.25, 0.5, 1, 3, 6 and 24 h after the start of
study drug infusion and at 2, 5, 15, 30, 60, 120 and 240 min
after discontinuation of the study drug. Blood was drawn for
anti-hBNP antibody levels at baseline and between days 20
and 30. Four hours after discontinuation of study drug
infusion, the pulmonary wedge catheter was removed if
appropriate, and all previously prescribed medications could
resume. Subjects were observed and discharged after
follow-up examination. A follow-up telephone call was
made on day 7 and day 15 for assessment of adverse events
and vital status.
Data analysis. Data were double-key entered into the
Sponsor’s clinical database and validated with computerized
edit checks. All plasma hBNP and serum anti-hBNP
antibody determinations were performed by a single core
laboratory at Scios Inc. to ensure consistency. The analyses
of hemodynamic responses were performed on the “intent to
treat” population. All randomized subjects were included in
this population, and subjects are summarized according to
the treatment group to which they were randomly assigned.
The effect of treatment group was analyzed within the
framework of one-way analysis of variance. An overall
comparison of the four treatment groups was made with the
omnibus F test. Each nesiritide treatment group was com-
pared with the placebo group using a pairwise contrast.
Dose–response effect was examined by means of a linear
contrast on treatment group using equally spaced scores.
When an end point was represented as the change or
percent change from baseline, a one-sample t test was run
within each treatment group to test for a nonzero mean
change from baseline. This test used the within-group
estimate of variance, not the pooled estimate from the
analysis of variance model. All reported p values are two
sided. For this report, p , 0.05 is considered statistically
significant. All analysis results were obtained using SAS
software (Cary, North Carolina), version 6.12, running on a
Digital Equipment Corporation Alphaserver 4100 5/300.
RESULTS
Subject enrollment and baseline features. From 16 study
sites, 103 subjects were enrolled. Figure 1 is a flow diagram
which accounts for subjects from randomization through
the treatment period. No subjects were lost to follow-up. As
shown in Table 2, there were no significant differences in
demographic or baseline characteristics between treatment
groups.
Hemodynamics. Figure 2 shows the mean observed values
for PCWP, SVR, SBP and CI in all treatment groups
during the 24-h infusion and the 4-h follow-up. As early as
1 h after the initiation of study drug (the first time point
assessed), PCWP was significantly reduced below baseline.
Mean decreases (6SD) in PCWP from baseline at 1 h in
the placebo and 0.015-, 0.03-, and 0.06-mg/kg/min nesirit-
ide dose groups were 1.6 6 4.8, 5.6 6 7.6, 3.5 6 7.6 and
8.4 6 7.1 mm Hg, respectively (p 5 0.002 [linear con-
trast]). At 1 h corresponding mean percent decreases in
PCWP from baseline were 5 6 20%, 17 6 19%, 12 6 28%
and 28 6 23% mm Hg in the placebo and three nesitiride
dose groups, respectively (p 5 0.001 [linear contrast]). Peak
hemodynamic effects were evident by 3 to 6 h of infusion in
all nesiritide groups with 27 6 23% to 39 6 22% reductions
in PCWP from baseline. At 24 h of infusion, PCWP was
still significantly decreased below baseline values in two of
the three nesiritide groups, group 2 and group 4. By 4 h
after discontinuation of infusion, PCWP had essentially
returned to pretreatment values in all groups; mean de-
creases in PCWP from baseline were 2.1 6 5.1, 3.7 6 10.0,
Figure 1. Flow diagram of subjects from randomization through
the treatment period. 1Did not meet entry hemodynamic criteria.
2Subjects whose infusion terminated before 22 h. BP 5 blood
pressure; CHF 5 worsening heart failure; CI 5 cardiac index;
NA 5 not applicable; PCWP 5 pulmonary capillary wedge
pressure. Downward arrows: excessively decreased.
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0.7 6 8.3 and 3.2 6 9.6 mm Hg in the placebo and three
nesiritide dose groups, respectively (p 5 0.648 [omnibus F
test]). There was no evidence for a “rebound effect,” that is,
an increase of PCWP to values higher than pretreatment
levels, in any of the nesiritide dose groups.
Figure 2 also details the effects of nesiritide and placebo
on SVR, CI and SBP, respectively. Nesiritide resulted in
statistically significant reductions in SVR and SBP and
increases in CI relative to baseline in all three nesiritide dose
groups. Mean CI increased over baseline values in all three
nesiritide dose groups throughout the 24 h of infusion and
returned to baseline values within 4 h of discontinuing the
infusion. For example, in the 0.015-mg/kg/min nesiritide
dose group, mean CI at baseline was 1.8 6 0.4 liters/min/
m2. After 3 and 24 h of nesiritide, mean CI had increased
to 2.2 6 0.4 and 2.1 6 0.6 liters/min/m2, respectively;
within 4 h of discontinuing nesiritide, mean CI had de-
creased to 1.9 6 0.4 liters/min/m2. Nesiritide also resulted
in statistically significant reductions in MRAP (peak de-
crease of 3.8 6 3.1 to 5.2 6 5.1 mm Hg by 6 h; p # 0.044
[pairwise contrast]) and pulmonary artery pressures (peak
decrease in mean pulmonary artery pressure of 7.7 6 10.7 to
10.5 6 7.9 mm Hg by 6 h; p # 0.001 [pairwise contrast])
compared with placebo. Peak changes in stroke volume
index by 6 h were 20.9 6 5.1, 16.1 6 7.2, 1 3.1 6 6.9 and
16.1 6 7.3 ml/beat/m2 in the placebo and three respective
nesiritide dose groups (p 5 0.001, pairwise contrast for the
0.015- and the 0.06-mg/kg/min nesiritide dose groups
relative to placebo). Pulmonary vascular resistance also
tended to decrease during infusion of all three doses of
nesiritide (peak decreases of 51 6 157 to 68 6 233
dyn/s/cm25), although these changes did not reach statis-
tical significance. Heart rate did not change appreciably
during nesiritide infusion, although there was a trend
toward a decrease in heart rate during infusion in the 0.015-
and 0.03-mg/kg/min dose groups and an increase in the
0.06-mg/kg/min dose group. Table 3 specifically addresses
the hemodynamic changes evident after 3 and 24 h of
infusion in those patients who continued to receive drug at
3 and at least 22 h. These data confirm a significant
pharmacologic response at 3 and 24 h in all hemodynamic
parameters, despite the fact that 2, 6, 8 and 12 subjects in
the four groups, respectively, underwent a 50% decrease in
infusion dose (all but one dose decrease in group 1 and one
in group 2 were protocol-specified for excessive hemody-
namic response). At 3 h of infusion, before the majority of
dose reductions and treatment withdrawals had occurred, all
hemodynamic parameters also show a significant dose–
response relationship by linear contrast.
Urine output/diuretic use. During the 24-h treatment
period, net urine output or urine sodium excretion were not
Table 2. Demographics and Baseline Characteristics
Characteristic
Placebo
(n 5 29)
Nesiritide
0.015 mg/kg/min
(n 5 22)
Nesiritide
0.03 mg/kg/min
(n 5 26)
Nesiritide
0.06 mg/kg/min
(n 5 26)
All Subjects
(n 5 103)
Age* (yr) 54 6 8 57 6 12 57 6 13 58 6 12 56 6 11
Male (%) 72 82 81 88 81
Race
White 10 (34%) 15 (68%) 14 (54%) 17 (65%) 56 (54%)
Black 9 (31%) 6 (27%) 6 (23%) 5 (19%) 26 (25%)
Hispanic 7 (24%) 1 (5%) 5 (19%) 3 (12%) 16 (16%)
Asian 0 (0%) 0 (0%) 1 (4%) 1 (4%) 2 (2%)
Weight* (kg) 77 6 18 90 6 25 80 6 21 80 6 21 81 6 21
NYHA Class
II 0 (0%) 2 (9%) 2 (8%) 2 (8%) 6 (6%)
III 21 (72%) 14 (64%) 13 (50%) 15 (58%) 63 (61%)
IV 8 (28%) 6 (27%) 11 (42%) 9 (35%) 34 (33%)
LVEF* (%) 19 6 7 22 6 7 19 6 7 24 6 7 21 6 7
HF etiology
Ischemia 17 (59%) 11 (50%) 14 (54%) 16 (62%) 58 (56%)
IDC 3 (10%) 5 (23%) 6 (23%) 5 (19%) 19 (18%)
Other 9 (31%) 6 (27%) 6 (23%) 5 (19%) 26 (25%)
Baseline hemodynamics
PCWP* (mm Hg) 28 6 6 30 6 8 27 6 5 29 6 7 29 6 6
SBP* (mm Hg) 113 6 16 123 6 22 113 6 17 119 6 23 116 6 20
SVR* (dyn/s/cm25) 1,704 6 683 1,782 6 757 1,619 6 821 1,719 6 739 1,704 6 738
CI* (liters/min/m2) 1.9 6 0.4 1.8 6 0.4 1.9 6 0.5 1.9 6 0.4 1.9 6 0.4
Plasma hBNP* (pg/ml) 595 6 759 831 6 692 836 6 630 790 6 1,118 NA
*Mean values 6 SD presented.
hBNP 5 human b-type natriuretic peptide; HF 5 heart failure; IDC 5 idiopathic dilated cardiomyopathy; LVEF 5 left ventricular ejection fraction; NA 5 not available;
SBP 5 systemic systolic blood pressure; SVR 5 systemic vascular resistance. Other abbreviations as in Table 1.
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greater in any of the nesiritide groups than in the placebo
group. Mean net urine output in the placebo and three
nesiritide ascending dose groups were 475, 291, 2237 and
2137 ml/24 h (p 5 0.113, omnibus F test). Mean urine
sodium excretion in the placebo and three nesiritide ascend-
ing dose groups was 156, 85, 106 and 147 mEq/24 h (p 5
0.369, omnibus F test). Diuretics were administered during
the 24-h study drug infusion in 66%, 50%, 54% and 46% of
subjects in the placebo and three nesiritide ascending dose
groups, respectively.
Study drug compliance. Excessive decreases in PCWP
during drug infusion requiring a protocol-specified dose
reduction occurred in 0 (0%), 4 (18%), 7 (27%) and 9 (35%)
subjects in the placebo and three ascending dose nesiritide
groups, respectively (p 5 0.002 [trend test]). Hypotension
led to dose reduction in an additional 1 (3%), 1 (5%), 1 (4%)
and 3 (12%) subjects in the placebo and three ascending
nesiritide groups, respectively. Five placebo subjects and one
subject in the 0.03-mg/kg/min nesiritide dose group termi-
nated study drug infusion prematurely due to worsening
congestive HF and were therefore categorized as treatment
failures (p 5 0.014 [trend test]). Premature termination of
study drug infusion because of hypotension or excessive
decreases in PCWP was dose related, reported in 0, 0, 2,
and 6 subjects in the placebo and 0.015-, 0.03- and
0.06-mg/kg/min nesiritide dose groups, respectively.
Safety. A 24-h continuous IV infusion of nesiritide was
generally well tolerated. The most frequently reported
adverse events during nesiritide infusion were decreases in
blood pressure and excessively decreased PCWP. These
events were dose related and are consistent with the phar-
macologic action of the drug. Hypotension during study
drug infusion was reported in 2 (7%), 1 (5%), 3 (12%) and
7 (27%) of the subjects in the placebo and 0.015-, 0.03- and
0.06-mg/kg/min nesiritide dose groups, respectively (p 5
0.027 [trend test]). However, the hypotension was often
asymptomatic and usually did not require intervention.
Symptomatic hypotension during study drug infusion was
reported in only 2 (7%), 1 (5%), 1 (4%) and 4 (15%) of the
subjects in the placebo and three ascending dose groups,
respectively (p 5 0.346 [trend test]). Nausea during study
drug infusion was reported in 0 (0%), 2 (9%), 0 (0%) and 4
(15%) of the subjects in the placebo and 0.015-, 0.03- and
0.06-mg/kg/min nesiritide dose groups, respectively (p 5
0.068 [trend test]). No other adverse events appeared to be
associated with nesiritide administration in a dose-related
manner.
Nonsustained ventricular tachycardia was reported during
study drug infusion in three subjects, all of whom were in
the 0.03-mg/kg/min nesiritide dose group. During the two
weeks after study drug administration, nonsustained ven-
tricular tachycardia was reported in two placebo subjects and
in three, five and zero subjects in the three ascending dose
nesiritide groups, respectively. The lack of a dose-related
incidence of nonsustained ventricular tachycardia during
and after study drug administration suggests that these
events are consistent with the expected prevalence of an
Figure 2. Mean observed hemodynamic values: results from baseline (BL) through 24 h of infusion (inf) and 4 h postinfusion. (A)
Pulmonary capillary wedge pressure units are mm Hg. (B) Cardiac index units are liters/min/m2. (C) Systemic systolic blood pressure units
are mm Hg. (D) Systemic vascular resistance units are dyn/s/cm25. Open squares: placebo; closed circles: 0.015 mg/kg/min; closed
triangles: 0.03 mg/kg/min; open circles: 0.06 mg/kg/min.
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underlying substrate for ventricular arrhythmias in this
study population. Sustained ventricular tachycardia was not
reported in any subject through day 14.
Three deaths occurred during the 15-day study follow-up
period, one each in the placebo group, the 0.03-mg/kg/min
nesiritide group and the 0.06-mg/kg/min nesiritide group.
Two additional deaths were reported after day 15, both in
the placebo group. None of these deaths was believed to be
study related.
None of the subjects tested (n 5 59) developed anti-
hBNP antibody in the follow-up period.
Human b-type natriuretic peptide blood levels. Blood
levels of hBNP achieved steady state before 3 h of infusion.
Three-hour levels for group 1 (placebo) were 835 6 989
pg/ml, and for groups, 2, 3 and 4 were 2,985 6 1,440,
3,711 6 2,063 and 6,456 6 4,272 pg/ml, respectively.
DISCUSSION
This double-blind, placebo-controlled study of 103 subjects
with symptomatic decompensated HF showed that a 24-h
continuous IV infusion of nesiritide resulted in rapid and
sustained beneficial hemodynamic effects and was well
tolerated in this patient population. As early as 1 h after the
start of therapy (the first time point measured in this study),
as well as after 24 h of infusion, the hemodynamic effects of
nesiritide include a marked reduction in preload coupled
with a decrease in afterload, facilitating an increase in stroke
volume and cardiac output. Hemodynamic parameters
promptly returned to baseline after the infusion was discon-
tinued after 24 h without evidence of a rebound effect.
Hemodynamic effects. The pharmacologic effect of hBNP
at the cellular level is mediated by increases in cyclic
guanosine monophosphate which lead to relaxation of
vascular smooth muscle (12). Hemodynamically, these ef-
fects manifest as clinically significant balanced vasodilation,
reducing both systemic vascular resistance and central ve-
nous pressure with no evidence of tolerance. This balanced
vasodilator effect facilitates improved forward cardiac output
at reduced filling pressures, almost certainly by redistribu-
tion of mitral regurgitant flow, as observed with other
vasodilators (13,14). Reduction of systemic venous pressure
may also improve left ventricular function in some advanced
HF patients through ventricular interdependence (15,16).
In addition, reduction in left ventricular filling pressure may
improve myocardial perfusion, resulting in improvement in
both systolic and diastolic function, particularly in patients
with obstructive coronary disease (17).
Nesiritide is not an inotrope and is not dependent on
adrenergic receptors or cyclic adenosine monophosphate for
pharmacologic efficacy. Our data show no increase in either
heart rate or systolic blood pressure during nesiritide infu-
sion, indicating that the beneficial hemodynamic effects
produced do not entail an increase in myocardial oxygen
consumption.Ta
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Effects on diuresis. We did not observe greater urine
output during the nesiritide infusion compared with placebo
in this study. This is difficult to interpret given the lack of
baseline urine output measurements as well as the discor-
dant use of diuretics between treatment groups during study
drug infusion. However, the lack of an increase in urine
output during nesiritide infusion does conflict with the
independent findings of Marcus et al. (10) and LeJemtel et
al. (18, personal communication), whose studies describe a
moderate increase in urine output during nesiritide infusion
compared with placebo.
Clinical trial design. The design of this trial required a
trade-off between assessment of therapeutic efficacy, which
would have allowed more liberal dose titration, and assess-
ment of the hemodynamic changes associated with the
specific drug doses. The hemodynamic results observed
most likely underestimate the sustained hemodynamic ben-
efits of nesiritide because of dose reductions and subject
withdrawals, in essence removing several patients with
prompt and beneficial responses to the drug from continued
treatment. The lack of a linear dose–response relationship in
the observed hemodynamic responses in this intent-to-treat
population might represent statistical variation due to small
sample size or the effect of down-titration and withdrawal
for excessive pharmacologic response. A linear dose re-
sponse to increasing doses of nesiritide has been docu-
mented in other studies (10,18). Nonetheless, all three doses
of nesiritide administered in this study resulted in beneficial
effects on cardiac hemodynamics, such as decreases in
PCWP and increases in CI.
Safety. Although the highest dose studied here (0.06 mg/
kg/min) resulted in the greatest effects on most hemody-
namic parameters, it was also associated with a higher
incidence of adverse events (such as hypotension and nau-
sea) than the lower two doses, and premature terminations
of study drug infusion due to these adverse events were more
frequent in this group. Conversely, adverse events in the two
lower dose groups were infrequent and generally tolerable.
This suggests that doses of nesiritide in the range of 0.015
to 0.03 mg/kg/min provide an optimal safety/efficacy profile
for this clinical indication.
Conclusions. The rapid and sustained beneficial hemody-
namic effects observed during nesiritide administration in
this study support the use of this agent as a first-line
intravenous therapy for patients with symptomatic, decom-
pensated congestive HF.
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